Cargando…

Chimeric antigen receptor engineered natural killer cells for cancer therapy

Natural killer (NK) cells, a unique component of the innate immune system, are inherent killers of stressed and transformed cells. Based on their potent capacity to kill cancer cells and good tolerance of healthy cells, NK cells have been successfully employed in adoptive cell therapy to treat cance...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zhang, Yalan, Zhou, Weilin, Yang, Jiangping, Yang, Jinrong, Wang, Wei
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10413722/ https://www.ncbi.nlm.nih.gov/pubmed/37563648 http://dx.doi.org/10.1186/s40164-023-00431-0

Ejemplares similares

Chimeric antigen receptor-engineered natural killer cells for cancer immunotherapy
por: Yilmaz, Ahmet, et al.
Publicado: (2020)

Chimeric antigen receptor natural killer (CAR-NK) cell design and engineering for cancer therapy
por: Gong, Ying, et al.
Publicado: (2021)

Chimeric Antigen Receptor Expressing Natural Killer Cells for the Immunotherapy of Cancer
por: Mehta, Rohtesh S., et al.
Publicado: (2018)

Utilizing Chimeric Antigen Receptors to Direct Natural Killer Cell Activity
por: Hermanson, David L., et al.
Publicado: (2015)

Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
por: Elahi, Reza, et al.
Publicado: (2021)

Engineering of chimeric natural killer cell receptors to develop precision adoptive immunotherapies for cancer
por: Obajdin, J., et al.
Publicado: (2020)

Advancement of chimeric antigen receptor-natural killer cells targeting hepatocellular carcinoma
por: Dai, Kai, et al.
Publicado: (2021)

Chimeric antigen receptor natural killer cells: a promising antitumor immunotherapy
por: Wang, Yan, et al.
Publicado: (2023)

Therapeutic Targeting of Follicular T Cells with Chimeric Antigen Receptor-Expressing Natural Killer Cells
por: Reighard, Seth D., et al.
Publicado: (2020)

Development of c-MET-specific chimeric antigen receptor-engineered natural killer cells with cytotoxic effects on human liver cancer HepG2 cells
por: Liu, Bing, et al.
Publicado: (2019)

Intracranial injection of natural killer cells engineered with a HER2-targeted chimeric antigen receptor in patients with recurrent glioblastoma
por: Burger, Michael C, et al.
Publicado: (2023)

Targeting human leukocyte antigen G with chimeric antigen receptors of natural killer cells convert immunosuppression to ablate solid tumors
por: Jan, Chia-Ing, et al.
Publicado: (2021)

The establishment of polypeptide PSMA‐targeted chimeric antigen receptor‐engineered natural killer cells for castration‐resistant prostate cancer and the induction of ferroptosis‐related cell death
por: Wu, Liyuan, et al.
Publicado: (2022)

Enhanced Cytotoxicity of Natural Killer Cells following the Acquisition of Chimeric Antigen Receptors through Trogocytosis
por: Cho, Fu-Nan, et al.
Publicado: (2014)

Chimeric antigen receptor-natural killer cells: Novel insight into immunotherapy for solid tumors (Review)
por: Peng, Xiaobo, et al.
Publicado: (2021)

Engineering Chimeric Antigen Receptors
por: Kulemzin, S. V., et al.
Publicado: (2017)

Epigenetic engineering for optimal chimeric antigen receptor T cell therapy
por: Ito, Yusuke, et al.
Publicado: (2022)

Engineering chimeric antigen receptor T cells for solid tumour therapy
por: Liu, Longwei, et al.
Publicado: (2022)

Chimeric Antigen Receptor-Engineered T Cells for Immunotherapy of Cancer
por: Cartellieri, Marc, et al.
Publicado: (2010)

Engineering chimeric antigen receptor-T cells for cancer treatment
por: Ye, Baixin, et al.
Publicado: (2018)

Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Purinergic targeting enhances immunotherapy of CD73(+) solid tumors with piggyBac-engineered chimeric antigen receptor natural killer cells
por: Wang, Jiao, et al.
Publicado: (2018)

Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer
por: Yang, Shuo, et al.
Publicado: (2020)

Engineering better chimeric antigen receptor T cells
por: Zhang, Hao, et al.
Publicado: (2020)

Erratum to: Chimeric antigen receptor (CAR)-modified natural killer cell-based immunotherapy and immunological synapse formation in cancer and HIV
por: Liu, Dongfang, et al.
Publicado: (2017)

Natural Killer Cells and Current Applications of Chimeric Antigen Receptor-Modified NK-92 Cells in Tumor Immunotherapy
por: Zhang, Jianguang, et al.
Publicado: (2019)

Redirected Primary Human Chimeric Antigen Receptor Natural Killer Cells As an “Off-the-Shelf Immunotherapy” for Improvement in Cancer Treatment
por: Oberschmidt, Olaf, et al.
Publicado: (2017)

Engineering and Design of Chimeric Antigen Receptors
por: Guedan, Sonia, et al.
Publicado: (2018)

Engineering enhanced chimeric antigen receptor-T cell therapy for solid tumors
por: Neeser, A., et al.
Publicado: (2023)

Current Advances in Immunotherapy for Acute Leukemia: An Overview of Antibody, Chimeric Antigen Receptor, Immune Checkpoint, and Natural Killer
por: Shang, Yufeng, et al.
Publicado: (2019)

Anticancer traits of chimeric antigen receptors (CARs)-Natural Killer (NK) cells as novel approaches for melanoma treatment
por: Bahmanyar, Maryam, et al.
Publicado: (2022)

Multi-antigen-targeted chimeric antigen receptor T cells for cancer therapy
por: Han, Xiao, et al.
Publicado: (2019)

Chimeric antigen receptor T-cell therapy for T-ALL and AML
por: Wei, Wenwen, et al.
Publicado: (2022)

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia
por: Müller, Stephan, et al.
Publicado: (2020)

Chimeric antigen receptor T-cell therapy
por: Burge, Cale, et al.
Publicado: (2023)

Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
por: Hillerdal, Victoria, et al.
Publicado: (2015)

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges
por: Han, Ethan Q, et al.
Publicado: (2013)

Preclinical Evaluation of Invariant Natural Killer T Cells Modified with CD38 or BCMA Chimeric Antigen Receptors for Multiple Myeloma
por: Poels, Renée, et al.
Publicado: (2021)

Anti-TIM3 chimeric antigen receptor-natural killer cells from engineered induced pluripotent stem cells effectively target acute myeloid leukemia cells
por: Klaihmon, Phatchanat, et al.
Publicado: (2023)

Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy
por: Dai, Hanren, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_nbi6cori69gpelnlf7svs7n096